Answers are grounded in this paper and cite their sources.
Lumipulse CSF biomarker measures with validated cut-points have clinical utility in identifying AD pathology.
No takes yet. Share an insight, caveat, or question.
Kaplow et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: